MedTrace Logo

A Study of APG-3288 in Relapsed/Refractory Blood Cancers

NCT07424833 · Status: RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 180

Last updated 2026-07-30

No results posted yet for this study

Summary

This is a Phase I, multicenter, open-label, two-stage study of APG-3288 monotherapy, aiming to determine the Maximum Tolerated Dose (MTD) and Recommended Phase 2 Dose (RP2D) of APG-3288 administered orally once daily in patients with relapsed/refractory (R/R) hematologic malignancies.

Conditions

  • Relapsed/Refractory Hematological Malignancies
  • Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Leukemia (CLL/SLL
  • Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL; Including Richter Transformation)
  • Relapsed/Refractory Mantle Cell Lymphoma (MCL)
  • Relapsed/Refractory Waldenström Macroglobulinemia (WM)
  • Relapsed/Refractory Marginal Zone Lymphoma (MZL)
  • Relapsed/Refractory Follicular Lymphoma (FL)

Interventions

DRUG

APG-3288

Orally administered daily; 28 days per cycle.

Sponsors & Collaborators

  • Ascentage Pharma Group Inc.

    lead INDUSTRY

Principal Investigators

  • Keshu Zhou, M.D.,Ph.D. · Henan Cancer Hospital

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-08-31
Primary Completion
2029-12-31
Completion
2031-12-31
FDA Drug
Yes

Countries

  • United States
  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07424833 on ClinicalTrials.gov